- Focus Areas
First Report Highlighting NASG Use Outside of Clinical Trials Published by Pathfinder International and the University of California San Francisco
What is the Non-Pneumatic
Pathfinder International is thrilled to announce the publication of "Comorbidities and Lack of Blood Transfusion May Negatively Affect Maternal Outcomes of Women with Obstetric Hemorrhage Treated with NASG" in the PLOS ONE Open Access journal.
Co-authored by Pathfinder and the University of California San Francisco’s Safe Motherhood Program, the paper outlines findings from data collected on more than 1,000 women who were treated with the non-pneumatic anti-shock garment (NASG) for shock from obstetric hemorrhage during the implementation of Pathfinder International’s Clinical and Community Action to Address Postpartum Hemorrhage Project in Nigeria.
The report is the first of its kind published on the use of the NASG outside of clinical trials and was produced to share our experience in using the NASG throughout the past five years, with a focus on the factors related to positive and negative outcomes following the use of the NASG.
The findings reinforce and demonstrate many of Pathfinder and the University of California San Francisco’s hypotheses about the NASG:
- Use of the NASG reduces mortality among women in shock due to obstetric causes when used in real-world settings.
- The NASG is not a replacement for blood transfusions or definitive care. It is a first aid device that will help overcome delays in the system. A Continuum of Care Approach (from prevention to definitive treatment) is necessary for best maternal health outcomes.
- A staff well-trained to handle complicated emergency obstetrical care should be looking not only at hemorrhage, but for co-morbidities that might need other treatments (particularly eclampsia and sepsis).
- Well-trained staff should recognize and manage women carrying dead fetuses rapidly before blood clotting problems develop.
- NASG use in real-world settings allows for evaluation and establishment of a knowledge base without the need for major epidemiological trials.
Results also show that mothers with certain conditions—a high number of previous deliveries or a life-threatening morbidity like eclampsia, for example—were more likely to die from postpartum hemorrhage. Women who died also received fewer intravenous infusions and blood transfusions than women who survived. This underscores the need for multi-system assessment and a comprehensive approach to the treatment of women with pregnancy complications, reinforcing Pathfinder’s commitment to a Continuum of Care Approach to address maternal mortality.
For more information, please contact firstname.lastname@example.org or call 617.972.1383.
Looking for a way to give back on #GivingTuesday? The mHealth Alliance lists nine different organizations, including Pathfinder International, that you can support to advance mhealth in low- and middle-income countries around the world.
Pathfinder is delighted to share that a friend of our maternal health work, Dr. Laura Stachel, has been nominated as one of CNN’s Top 10 Heroes of the Year.